Loading patent…
AssigneeAstraZeneca Ireland Limited
InventorsJoanne Irene BRODFUEHRER, Amendra Fernando Hewa DEWAGE, Hannah Szydlo GARDNER, Alison Patricia JOYCE, Amy Cotsonas KING, Maria Paquerette Galou LAMEYER, Kok Hong LIM, Laura Lin LOHSE, Nicholas Andrew MARZE, Denise Mary MURPHY, Alyssa Ann MYERS, Sze Pui TAM
Estimating the term…
Provided are improved cysteine proteases for specifically cleaving and inactivating immunoglobulin G. The improved cysteine pro-teases are useful in methods of treating diseases, disorders or conditions characterized by excessive levels of IgG antibodies, including autoimmune disorders and candidates for organ transplantation sensitized with anti-HLA antibodies, as well as for treating candidates for gene therapy with pre-existing neutralizing antibodies against recombinant vectors and re-dosing of subjects previously treated with a gene therapy vector.
An isolated cysteine protease that specifically cleaves immunoglobulin G (IgG) antibody molecules.
4-8. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
21-29. (canceled)
32-34. (canceled)
36-39. (canceled)
(canceled)
(canceled)
45-48. (canceled)
(canceled)
(canceled)
54-57. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.